Oxysterols and methods of use thereof
US-10259840-B2 · Apr 16, 2019 · US
US10723758B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10723758-B2 |
| Application number | US-201816028790-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 6, 2018 |
| Priority date | Jun 18, 2014 |
| Publication date | Jul 28, 2020 |
| Grant date | Jul 28, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, Y, R 1 , R 2a , R 2b , R 4a , R 4b , R 5a , R 5b , R 6a , R 6b , R 7 , and R 8 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
Opening claim text (preview).
What is claimed is: 1. A method of inducing sedation or anesthesia, comprising administering to a subject an effective amount of a compound having the following structure: or a pharmaceutically acceptable salt thereof. 2. A method for modulating an NMDA receptor in a subject having a CNS-related condition, comprising administering to the subject an effective amount of a compound having the following structure: or a pharmaceutically acceptable salt thereof, wherein the CNS-related condition is obsessive-compulsive disorder, posttraumatic stress disorder, social phobia, Alzheimer's disease and other forms of dementia, eating disorder, schizophrenia, autism spectrum disorders, pain, anti-NMDA receptor encephalitis, Huntington's disease, or Parkinson's disease.
containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton · CPC title
not covered by C07J31/003 · CPC title
Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006) · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Ophthalmic agents · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.